Efficacy and safety of subcutaneous interferon beta-1a in relapsing–remitting multiple sclerosis: Further outcomes from the IMPROVE study
- 15 January 2012
- journal article
- research article
- Published by Elsevier BV in Journal of the Neurological Sciences
- Vol. 312 (1), 97-101
- https://doi.org/10.1016/j.jns.2011.08.013
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosisMultiple Sclerosis Journal, 2010
- Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approachAnnals of Neurology, 2009
- Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week resultsMultiple Sclerosis Journal, 2008
- Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosisClinical Therapeutics, 2007
- Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology, 2006
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosisEuropean Journal of Neurology, 2005
- Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change AnalysisNeuroImage, 2002
- PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology, 2001
- Randomized controlled trial of interferon- beta-1a in secondary progressive MSNeurology, 2001
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998